Bayer/Onyx’s Nexavar Gets Liver Cancer Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Sorafenib becomes first systemic drug therapy approved for unresectable HCC.
You may also be interested in...
Bayer Oncology Keystone Nexavar Looks Good For Thyroid Indication
Adding indications for Nexavar is critical to Bayer HealthCare’s plan to become a major global player in cancer therapeutics, Bayer oncology leader says at ASCO.
Onyx Kicks Off Pipeline Expansion By Buying TS Inhibitor
Preclinical oncologic in-licensed from BTG offers opportunity in ovarian, lung, breast and colorectal cancers, biotech says.
Onyx Kicks Off Pipeline Expansion By Buying TS Inhibitor
Preclinical oncologic in-licensed from BTG offers opportunity in ovarian, lung, breast and colorectal cancers, biotech says.